Next Article in Journal
Mitochondrial Ataxias: Molecular Classification and Clinical Heterogeneity
Next Article in Special Issue
Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer’s Disease
Previous Article in Journal
Cortical Oxygenation during a Motor Task to Evaluate Recovery in Subacute Stroke Patients: A Study with Near-Infrared Spectroscopy
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Advances in Neurodegenerative Diseases

by
Vasileios Siokas
* and
Efthimios Dardiotis
Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly Biopolis, Mezourlo Hill, 41100 Larissa, Greece
*
Author to whom correspondence should be addressed.
Neurol. Int. 2022, 14(2), 336; https://doi.org/10.3390/neurolint14020027
Submission received: 17 March 2022 / Accepted: 24 March 2022 / Published: 28 March 2022
(This article belongs to the Collection Advances in Neurodegenerative Diseases)
A multitude of diseases presenting a wide variety of phenotypic appearances are included in neurodegenerative disorders. They are mainly characterized by the loss of specific populations of neural cells. Moreover, several pathophysiological mechanisms can lead to neuronal dysfunction and death, and thus, to neurodegenerative disorders. The accumulation of pathologic amyloid, dopaminergic neuron loss, excitotoxicity, lysosome dysfunction, mitochondrial dysfunction, defective axonal transport, oxidative stress, and defective microglia function are among them [1].
Both genetic and environmental factors confer susceptibility to neurodegenerative diseases [2]. For instance, coffee consumption, pesticide exposure, traumatic brain injury, infections, and smoking have been reported to modify the risk of the development of neurodegenerative diseases. Furthermore, there is accumulating evidence of the genetic contribution to the risk of neurodegenerative diseases development. So, there are monogenic forms of neurodegenerative disorders and also genetic variants that modify the risk of development of neurodegenerative diseases. Finally, there is also a complex interplay between the genetic and non-genetic factors possibly leading to neurodegenerative processes.
With the increase in the life expectancy of the population, the incidence of neurodegenerative diseases is constantly rising. Current therapeutic options for neurodegenerative disorders are mainly limited to the management of symptomatology [1]. Therefore, there is an unmet need to identify disease-modifying therapies targeting neurodegenerative disorders.
As such, highlighting the results of ongoing research and collecting the current available evidence are now more important than ever. The present Topical Collection (“Advances in Neurodegenerative Diseases”, available online: https://www.mdpi.com/journal/neurolint/special_issues/Advances_Neurodegenerative_Diseases (accessed on 17 March 2022) aims to cover the latest advancements in the field of neurodegeneration and neurodegenerative diseases. We invite authors to contribute original studies, reviews, meta-analyses, and related case reports regarding neurodegenerative diseases. All article types are welcome.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mehta, A.R.; Chataway, J.; Pal, S.; Parmar, M.K.B.; Chandran, S. Trials for neurodegenerative diseases: Time to innovate. Lancet Neurol. 2021, 20, 984. [Google Scholar] [CrossRef]
  2. Hou, Y.; Dan, X.; Babbar, M.; Wei, Y.; Hasselbalch, S.G.; Croteau, D.L.; Bohr, V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019, 15, 565–581. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Siokas, V.; Dardiotis, E. Advances in Neurodegenerative Diseases. Neurol. Int. 2022, 14, 336. https://doi.org/10.3390/neurolint14020027

AMA Style

Siokas V, Dardiotis E. Advances in Neurodegenerative Diseases. Neurology International. 2022; 14(2):336. https://doi.org/10.3390/neurolint14020027

Chicago/Turabian Style

Siokas, Vasileios, and Efthimios Dardiotis. 2022. "Advances in Neurodegenerative Diseases" Neurology International 14, no. 2: 336. https://doi.org/10.3390/neurolint14020027

APA Style

Siokas, V., & Dardiotis, E. (2022). Advances in Neurodegenerative Diseases. Neurology International, 14(2), 336. https://doi.org/10.3390/neurolint14020027

Article Metrics

Back to TopTop